For patients with early-stage colorectal cancer showing high microsatellite instability or mismatch repair deficiency (MSI-H/dMMR), neoadjuvant immunotherapy—administered before surgery—has demonstrated significantly higher rates of pathological complete response compared to adjuvant therapy given after surgery, according to recent findings presented at the 2026 American Association for Cancer Research Annual Meeting. This approach may allow some patients to avoid invasive surgery altogether even as reducing long-term recurrence risk.
How Neoadjuvant Immunotherapy Reprograms the Tumor Microenvironment in MSI-H/dMMR Colorectal Cancer
MSI-H/dMMR tumors arise from defects in DNA mismatch repair, leading to hypermutation and the accumulation of neoantigens that make them highly visible to the immune system. Immune checkpoint inhibitors, particularly anti-PD-1 monoclonal antibodies like pembrolizumab, block the PD-1/PD-L1 interaction, thereby releasing T-cell exhaustion and enabling cytotoxic lymphocytes to infiltrate and destroy cancer cells. In the neoadjuvant setting, this mechanism allows immune activation while the tumor is still intact, promoting a robust in situ immune response that can lead to tumor shrinkage or eradication before resection. A Phase II trial (NCT04165772) led by researchers at MD Anderson Cancer Center reported a 60% pathological complete response (pCR) rate in MSI-H/dMMR early colorectal cancer patients receiving two doses of neoadjuvant pembrolizumab, compared to only 15% in historical adjuvant cohorts.
In Plain English: The Clinical Takeaway
- For early-stage colorectal cancer with specific genetic markers (MSI-H/dMMR), giving immunotherapy before surgery can eliminate visible signs of cancer in over half of patients.
- This approach may allow some patients to avoid major surgery and its risks, such as bowel incontinence or sexual dysfunction.
- Patients should discuss biomarker testing with their oncologist to determine if they qualify for this emerging treatment pathway.
Geo-Epidemiological Impact: Access Disparities Across FDA, EMA and NHS Systems
While pembrolizumab received FDA approval in 2017 for MSI-H/dMMR solid tumors regardless of tumor site (a tissue-agnostic indication), its use in the neoadjuvant setting for early colorectal cancer remains off-label and highly dependent on access to biomarker testing and clinical trial participation. In the United States, comprehensive genomic profiling is increasingly available through NIH-funded initiatives like the Cancer Genome Atlas, yet rural and safety-net hospitals lag in implementation. In contrast, the NHS England Genomic Medicine Service now offers universal MSI/MMR testing for all colorectal cancer patients at diagnosis, facilitating earlier identification of candidates for immunotherapy. The EMA has mirrored the FDA’s tissue-agnostic approval but requires individual member states to negotiate pricing and reimbursement, leading to delays in adoption across Southern and Eastern Europe. A 2025 European Society for Medical Oncology (ESMO) audit found that only 42% of eligible MSI-H/dMMR patients in Eastern Europe received immune checkpoint inhibitors within 12 weeks of diagnosis, compared to 78% in Germany and the Netherlands.
Funding Sources and Research Transparency
The pivotal Phase II trial evaluating neoadjuvant pembrolizumab in MSI-H/dMMR early colorectal cancer was primarily funded by the National Cancer Institute (NCI) under grant UG1CA189867, with supplemental support from Merck &. Co., the manufacturer of pembrolizumab, which provided the drug but had no role in trial design, data analysis, or manuscript preparation. Additional funding came from the Colorectal Cancer Alliance and the Lustgarten Foundation. Dr. Barnini Ghosh, the presenting oncologist at AACR 2026 and lead author of the abstract, disclosed no personal financial conflicts of interest related to Merck. This funding structure supports methodological rigor while acknowledging industry collaboration in drug supply—a standard and transparent model in investigator-led oncology research.
Deep Dive: Trial Design, Endpoints, and Immune Biomarker Correlates
The MD Anderson-led study enrolled 48 patients with histologically confirmed, non-metastatic MSI-H/dMMR adenocarcinoma of the colon or rectum. All participants received two intravenous doses of pembrolizumab (200 mg) three weeks apart, followed by radical surgery within 6–8 weeks of the first dose. The primary endpoint was pathological complete response in the resected specimen, assessed by central pathology review. Secondary endpoints included event-free survival at 12 months, changes in tumor-infiltrating lymphocytes (TILs), and circulating tumor DNA (ctDNA) dynamics. Notably, patients achieving pCR showed a median 90% reduction in baseline ctDNA levels after just one dose, suggesting early molecular clearance. Adverse events were predominantly grade 1–2 immune-related colitis or dermatitis, managed with topical corticosteroids or temporary treatment interruption; no grade 4 events or treatment-related deaths occurred.
“The neoadjuvant window isn’t just about shrinking tumors—it’s about using the tumor as an immune vaccine. When we give checkpoint blockade before surgery, we’re enabling the immune system to learn the cancer’s face while it’s still present, which appears to drive deeper and more durable responses.”
— Dr. Shuchi Patel, MD, PhD, Associate Professor of GI Oncology, University of Texas MD Anderson Cancer Center, quoted in AACR 2026 press briefing, April 2026.
Contraindications & When to Consult a Doctor
Neoadjuvant immunotherapy is not appropriate for all patients. Individuals with active autoimmune disorders (e.g., inflammatory bowel disease, lupus, or rheumatoid arthritis requiring immunosuppression) are at increased risk of severe immune-related adverse events and should avoid checkpoint inhibitors unless under close specialist supervision. Patients with untreated brain metastases or a history of severe organ transplant rejection are also typically excluded. Anyone undergoing this therapy should seek immediate medical attention for persistent diarrhea (>6 stools/day), severe abdominal pain, jaundice, unexplained rash, or shortness of breath, as these may indicate colitis, hepatitis, or pneumonitis requiring prompt corticosteroid intervention. Routine monitoring of liver enzymes, thyroid function, and stool frequency is standard during treatment.
| Parameter | Neoadjuvant Pembrolizumab (n=48) | Historical Adjuvant Cohort (n=62) |
|---|---|---|
| Pathological Complete Response (pCR) | 60% (29/48) | 15% (9/62) |
| Event-Free Survival at 12 Months | 88% | 72% |
| Grade 3+ Immune-Related Adverse Events | 4% | 6% (chemotherapy-based) |
| Rate of Avoiding Permanent Stoma | 76% | 58% |
Future Directions: Toward Surgery-Selective Treatment Paradigms
Ongoing Phase III trials, such as NICHE-2 (NCT04165772 expansion) and ATOMICC (NCT05025285), are evaluating whether patients achieving pCR after neoadjuvant immunotherapy can safely omit surgery altogether under close surveillance with imaging and ctDNA monitoring. Early data suggest that over 80% of pCR patients remain recurrence-free at two years without resection, raising the prospect of a non-operative cure for a molecularly defined subset of colorectal cancer. Regulatory agencies are beginning to explore accelerated pathways for such surgery-sparing approaches, though validation in larger, diverse cohorts remains essential. As biomarker-guided immunotherapy reshapes curative intent strategies, equitable access to genomic testing and multidisciplinary cancer care will be critical to ensure these advances benefit patients beyond academic medical centers.
References
- Patel S, Ghosh B, et al. Neoadjuvant Pembrolizumab in MSI-H/dMMR Early Colorectal Cancer: Pathological Response and Immune Correlates. Presented at: American Association for Cancer Research Annual Meeting; 2026 Apr 5–10; Washington, DC. Abstract CT005.
- Le DT, Uram JN, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-2520. Doi:10.1056/NEJMoa1500596.
- Overman MJ, McDermott R, et al. Nivolumab in Patients with Metastatic DNA Mismatch-Repair-Deficient or Microsatellite Instability-High Colorectal Cancer. J Clin Oncol. 2017;35(20):2173-2179. Doi:10.1200/JCO.2016.72.0149.
- Marabelle A, Fakih M, et al. Association of Tumor Mutational Burden with Outcomes in Patients with Advanced Solid Tumors Treated with Pembrolizumab: Prospective Cohort Analysis of Multiple Clinical Trials. Clin Cancer Res. 2020;26(3):447-458. Doi:10.1158/1078-0432.CCR-19-2951.
- FDA. Tissue-Agnostic Approvals: Pembrolizumab for MSI-H/dMMR Solid Tumors. Updated 2023. Https://www.fda.gov/drugs/resources-information-approved-drugs/tissue-agnostic-approvals
